Loading…
Loading…
MANE (Veradermics, Incorporated) is a recent IPO.
It began trading on February 4, 2026, giving it under six months of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.
MANE does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See exactly how MANE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MANE and 80,000+ other tickers.
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy…
MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for hair loss. However, VDPHL01 still needs pivotal data to make it ready for a potential FDA submission. If approved, VDPHL01 would compete as a cash-pay prescription treatment for pattern hair loss, which would let MANE tap into a sizeable TAM.
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302' of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during th.
Veradermics, Incorporated (NYSE: MANE - Get Free Report)'s stock price gapped up before the market opened on Wednesday after Citigroup raised their price target on the stock from $135.00 to $160.00. The stock had previously closed at $110.17, but opened at $118.75. Citigroup currently has a buy rating on the stock. Veradermics shares last traded at
Veradermics Incorporated (NYSE:MANE) on Wednesday released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss.
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript